Team:HKUST-Hong Kong/content.html
From 2011.igem.org
(One intermediate revision not shown) | |||
Line 2: | Line 2: | ||
<head><title></title> | <head><title></title> | ||
<style type="text/css"> | <style type="text/css"> | ||
- | #globalWrapper { background- | + | #globalWrapper { |
- | + | background-image:url('https://static.igem.org/mediawiki/2011/6/63/Bottom.jpg'); background-attachment:fixed; border: none; margin: 0; padding: 0; width: 100%; height:100%;} | |
- | + | #footer { background-color: white; border: none; width: 620px; margin: 0 auto; padding: 0;} | |
- | # | + | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
.firstHeading { display: none;} | .firstHeading { display: none;} | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
</style> | </style> | ||
<style type="text/css"> | <style type="text/css"> | ||
- | |||
- | |||
- | |||
<!-- | <!-- | ||
Line 44: | Line 21: | ||
--> | --> | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
p{ | p{ | ||
Line 62: | Line 29: | ||
margin: 0px 20px 0px 20px; | margin: 0px 20px 0px 20px; | ||
text-align: justify; | text-align: justify; | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
} | } | ||
Line 88: | Line 46: | ||
<TR> | <TR> | ||
<TH ROWSPAN=3 BGCOLOR="#182828" width=600> | <TH ROWSPAN=3 BGCOLOR="#182828" width=600> | ||
- | <img src="https://static.igem.org/mediawiki/2011/0/0b/Igem_hkust.png" width=240 | + | <img src="https://static.igem.org/mediawiki/2011/0/0b/Igem_hkust.png" width=240 align=left style="margin: 20px 20px 20px 20px"> |
<br> | <br> | ||
<p align=justify> | <p align=justify> |
Latest revision as of 10:40, 26 October 2011
Greeting from the 2011 HKUST iGEM Team!
This is the 4th time HKUST has participated in this international synthetic biology competition. |
Overview |
Data Page |
---|---|
Acknowledgements |
|
|
|
Project Abstract It has often been assumed that when an antibiotic is introduced to a bacterial community, only cells that carry resistance genes will survive and proliferate. However, recent findings suggest that communities with a mixture of highly resistant (HR) and less resistant (LR) individuals are able to survive through ‘charity’ by HR individuals, which support LR individuals through indole signalling. Our team aims to interfere with this signalling through introducing a disruptor E. coli into the bacterial community. This new strain will be able to degrade indole using a mutated toluene-4-monooxygenase (T4MO). We hypothesize that LR cells in the community deprived of indole will undergo elimination at lower antibiotic concentrations. If this demonstration is successful, indole degradation might prove to be a possible strategy in boosting antibiotics effectiveness in medical practice against bacteria that rely on such signalling. Along the way, we will also create a new strain of E. coli that utilizes an essential gene (nadE) as the selection marker for transformation, allowing antibiotics-free transformation and plasmid maintenance for regular laboratory manipulation. This new transformation method can be adopted for future iGEM teams, reducing their use of antibiotics without increasing the complexity of the transformation protocol. |
Our Project Experiments and Results
Strain Construction |
Culture Tests |
Modeling Miscellaneous |
iGEM Resources The Team
iGEM Member List |
Contributions Achievements
Medal Requirements |
BioSafety BioBricks |
Human Practice |